ZYME
Zymeworks Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.07B
P/E Ratio
—
EPS
$-1.08
Beta
1.20
52W High
$29.75
52W Low
$10.86
50-Day MA
$25.25
200-Day MA
$20.91
Dividend Yield
—
Profit Margin
-76.60%
Forward P/E
—
PEG Ratio
0.00
About Zymeworks Inc. Common Stock
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in Vancouver, Canada.
Fundamentals
| Revenue (TTM) | $105.97M |
| Gross Profit (TTM) | $-31.04M |
| EBITDA | $-84.82M |
| Operating Margin | -1756.00% |
| Return on Equity | -26.70% |
| Return on Assets | -14.30% |
| Revenue/Share (TTM) | $1.41 |
| Book Value | $3.60 |
| Price-to-Book | 7.70 |
| Price-to-Sales (TTM) | 19.51 |
| EV/Revenue | 17.52 |
| EV/EBITDA | 0.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -91.90% |
| Shares Outstanding | $73.75M |
| Float | $68.82M |
| % Insiders | 1.26% |
| % Institutions | 99.61% |
Historical Volatility
HV 10-Day
33.66%
HV 20-Day
35.09%
HV 30-Day
35.49%
HV 60-Day
40.07%
HV Rank
7.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($40.08 target)
2
Strong Buy12
BuyData last updated: 4/30/2026